menu ☰
menu ˟

Protagonist raises $40 million for development of oral peptide drugs

17 Jul 2015
Protagonist Therapeutics announced it has finalized $40 million in Series C financing to advance oral peptide drugs for inflammatory bowel disease and other gastrointestinal diseases and disorders into clinical development, according to a press relea...

Click here to view the full article which appeared in Gastroenterology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.